Company news

European Pharma License Exchange (EuroPLX)

2013-10-11 16:22      

The development of high-tech enterprise requires continual technology innovation and rapid updating of information. Competition between pharmaceutical enterprises has been oriented to further innovation, human resources and technology from simple market competition. To ensure strong competitiveness in market competition at home and abroad, HNSP assigned representatives to Munich, Germany to participate in the European Pharma License Exchange held from June 10 to June 11, 2013 at Raucon International Merchandising Committee’s invitation.

EuroPLX is a top international communication platform providing pharma and biotechnology enterprises with market developing opportunities and licensing. The communication covers original new drugs, generics, medical devices and instruments, new drug delivery technology, etc. Topics of EuroPLX involves licensed development, license exchange and distribution cooperation. Participants also have discussions on some topics, such as R&D service, contract manufacture and the supply of APIs and intermediates.

During the EuroPLX, HNSP negotiated international cooperation issues with 23 international pharmaceutical enterprises and initially confirmed cooperation intentions with several enterprises, which offered further platform to the implementation of HNSP internationalization strategy.

We hold a firm belief that the advanced internationalized R&D and management philosophies of our international cooperative pharmaceutical enterprises will help to realize HNSP’s goal of internationalization more rapidly. HNSP engaging in internationalization platform will strive to make a great contribution to the economic development of Hainan Province.

上一篇:CPhI, ICSE & BioPh China 2013
下一篇:没有了